Home›Research›Compare›Semaglutide vs Tirzepatide
Peptide ComparisonSemaglutide vs Tirzepatide
Both are Metabolic peptides.
Semaglutide
Ozempic
Half-life: ~7 days (once-weekly dosing)
801 providers listed
Tirzepatide
Mounjaro
Half-life: ~5 days (once-weekly dosing)
536 providers listed
Semaglutide is carried by more providers on PeptideBase (801 vs 536); otherwise the two are closely matched on the measures we track.
Semaglutide
Evidence
Half-life
~7 days (once-weekly dosing)
Tirzepatide
Evidence
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| More provider options (801 vs 536) | Semaglutide |
| Dual GIP + GLP-1 receptor activation | Tirzepatide |
| Oral formulation available (Rybelsus) | Semaglutide |
| Greater avg. weight loss in phase 3 trials (SURMOUNT vs STEP) | Tirzepatide |
| Longer post-approval safety record (approved 2017 vs 2022) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Semaglutide
Tirzepatide
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
+5 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agoni…
+9 more
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Semaglutide
Tirzepatide
Where to source these peptides
Semaglutide
801 listed
Browse directory →
Providers offeringTirzepatide
536 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Semaglutide vs Tirzepatide — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/semaglutide/tirzepatide